OPHTHALMIC SITUATION OF THE PATIENTS WITH CHRONIC RENAL FAILURE UNDERGOING HEMODIALYSIS

Yıl 2025, Cilt: 35 Sayı: 4, 633 - 639, 29.08.2025

Ali Küçüködük , Mahmut Oğuz Ulusoy , Mehmet Atakan , Öznur Kal

https://doi.org/10.54005/geneltip.1644269

Öz

ABSTRACT
Background/Aims: Hemodialysis (HD) is a unique treatment modality for patients with end-stage chronic renal failure (ESCRF). A wide range of ophthalmologic findings such as refractive changes, dry eye, increased intraocular pressure and retinal hemorrhage can be seen in these patients. In this study, we aimed to evaluate the ophthalmological status of hemodialysis patients.
Methods: A total of 504 eyes of 252 patients with ESCRF undergoing hemodialysis were included in the study. Renal failure, hemodialysis and additional disease data were evaluated along with demographic data of all patients. All participants underwent a total ophthalmological examination including visual acuity, intraocular pressure, detailed anterior and posterior segment examination.
Results: The mean age was 65.2113.15 years, and the mean hemodialysis time was 4.954.25 years. 237 (47.2%) of 504 eyes were pseudo-phakic and 170 (33.7%) had cataracts at different stages. Diabetic retinopathy (DRP) findings were detected in a total of 148 (26.4%) eyes. Age-related macular degeneration (AMD) findings at various stages were observed in 112 eyes (22.1%), while epiretinal membranes were detected in 60 eyes (11.9%). Dry eye findings were observed in 94 cases (37.1%) and glaucoma was detected in 20 cases.
Conclusions: The most common sight-threatening condition in ESCRF patients appears to be cataract and the most common ocular surface problem was dry eye disease. While various retinal pathologies were observed in a significant part of the patients, the frequency of proliferative DRP was found to be higher than that in the diabetic population.

Anahtar Kelimeler

hemodialysis , chronic renal disease , renal failure , ophthalmologic findings , visual loss

HEMODİYALİZ YAPILAN KRONİK BÖBREK YETMEZLİĞİ HASTALARININ OFTALMOLOJİK DURUMLARI

Öz

ÖZ
Amaç: Hemodiyaliz (HD), son dönem kronik böbrek yetmezliği (SDKBY) olan hastalar için özel bir tedavi yöntemidir. Bu hastaların büyük bir kısmında kırma kusurları, göz kuruluğu, göz içi basıncı artışı ve retina kanaması gibi çok çeşitli oftalmolojik bulgular görülebilmektedir. Bu çalışmada hemodiyaliz hastalarının oftalmolojik durumlarını değerlendirmeyi amaçladık.
Gereç ve yöntem: Hemodiyalize giren 252 SDKBY hastasının toplam 504 gözü çalışmaya dahil edildi. Tüm hastaların demografik verilerinin yanı sıra böbrek yetmezliği, hemodiyaliz ve ek hastalık verileri de değerlendirildi. Tüm katılımcılara görme keskinliği, göz içi basıncı, detaylı ön ve arka segment muayenesini içeren tam oftalmolojik muayene yapıldı.
Bulgular: Ortalama yaş 65,2113,15, ortalama hemodiyaliz süresi 4,954,25 yıl olarak hesaplandı. 504 gözün 237'si (%47,2) psödofakik iken, 170'inde (%33,7) farklı evrelerde katarakt mevcuttu. Toplam 148 (%26,4) gözde diyabetik retinopati (DRP) bulguları saptandı. 112 gözde (%22,1) çeşitli evrelerde yaşa bağlı makula dejenerasyonu (YBMD) bulguları gözlenirken, 60 gözde (%11,9) epiretinal membran tespit edildi. Olguların 94'ünde (%37,1) kuru göz bulguları, 20'sinde ise glokom saptandı (%3,9).
Sonuç: Bu çalışmada SDKBY hastalarında en sık görülen görmeyi tehdit eden durumun katarakt, en sık görülen oküler yüzey sorununun ise kuru göz hastalığı olduğu gözlemlenmiştir. Hastaların önemli bir kısmında çeşitli retina patolojileri gözlenirken proliferatif DRP sıklığının diyabetik popülasyona göre daha yüksek olduğu görülmüştür.

Anahtar Kelimeler

hemodiyaliz , kronik böbrek hastalığı , böbrek yetmezliği , oftalmolojik bulgular , görme kaybı

Kaynakça

• 1. Sgambat K, Cheng YI, Charnaya O, Moudgil A. The prevalence and outcome of children with failure to thrive after pediatric kidney transplantation. Pediatr Transplant. 2019;23(1):e13321.
• 2. Agarwal R. Defining end-stage renal disease in clinical trials: a framework for adjudication. Nephrol Dial Transplant. 2016;31(6):864-867.
• 3. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;20(12):2587-2593.
• 4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
• 5. Evans RD, Rosner M, editors. Fellows’ forum: Ocular abnormalities associated with advanced kidney disease and hemodialysis. Seminars in dialysis; 2005: Wiley Online Library.
• 6. Wong CW, Lamoureux EL, Cheng CY, Cheung GC, Tai ES, Wong TY, et al. Increased Burden of Vision Impairment and Eye Diseases in Persons with Chronic Kidney Disease - A Population-Based Study. EBioMedicine. 2016;5:193-197.
• 7. Mullaem G, Rosner MH. Ocular problems in the patient with end-stage renal disease. Semin Dial. 2012;25(4):403-407.
• 8. Nusinovici S, Sabanayagam C, Teo BW, Tan GSW, Wong TY. Vision Impairment in CKD Patients: Epidemiology, Mechanisms, Differential Diagnoses, and Prevention. Am J Kidney Dis. 2019;73(6):846-857.
• 9. Rim TH, Yoon CY, Park HW, Chung EJ. Association Between Starting Hemodialysis for End-Stage Renal Disease and Incident Cataract Surgery: A 12-Year Nationwide Cohort Study. Invest Ophthalmol Vis Sci. 2016;57(3):1112-1119.
• 10. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615-621.
• 11. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640-650.
• 12. Aktaş Z, Ozdek S, Asli Dinç U, Akyürek N, Atalay V, Güz G, et al. Alterations in ocular surface and corneal thickness in relation to metabolic control in patients with chronic renal failure. Nephrology (Carlton). 2007;12(4):380-385.
• 13. Kal Ö, Ulusoy MO, Kal A, Tanriaşki G, Cezairlioğlu Ş. Evaluation of Dry Eye Using Anterior Segment Optical Coherence Tomography in Patients With End-Stage Renal Disease Undergoing Hemodialysis. Ther Apher Dial. 2018;22(2):104-108.
• 14. Costagliola C, Iuliano G, Menzione M, Simonelli F, Tortori A, Masturzi B, et al. Systemic human diseases as oxidative risk factors in cataractogenesis. II. Chronic renal failure. Exp Eye Res. 1990;51(6):631-635.
• 15. Wong CW, Wong TY, Cheng CY, Sabanayagam C. Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways. Kidney Int. 2014;85(6):1290-1302.
• 16. Bajracharya L, Shah DN, Raut KB, Koirala S. Ocular evaluation in patients with chronic renal failure--a hospital based study. Nepal Med Coll J. 2008;10(4):209-214.
• 17. Deva R, Alias MA, Colville D, Tow FK, Ooi QL, Chew S, et al. Vision-threatening retinal abnormalities in chronic kidney disease stages 3 to 5. Clin J Am Soc Nephrol. 2011;6(8):1866-1871.
• 18. Sariyeva Ismayılov A, Aydin Guclu O, Erol HA. Ocular manifestations in hemodialysis patients and short-term changes in ophthalmologic findings. Ther Apher Dial. 2021;25(2):204-210.
• 19. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98(7):1128-1134.
• 20. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2000;130(5):658-663.
• 21. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. Jama. 2007;297(16):1793-1800.
• 22. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology. 1999;106(6):1056-1065.
• 23. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738.
• 24. Weiner DE, Tighiouart H, Reynolds R, Seddon JM. Kidney function, albuminuria and age-related macular degeneration in NHANES III. Nephrol Dial Transplant. 2011;26(10):3159-3165.
• 25. Xing C, Sivakumaran TA, Wang JJ, Rochtchina E, Joshi T, Smith W, et al. Complement factor H polymorphisms, renal phenotypes and age-related macular degeneration: the Blue Mountains Eye Study. Genes Immun. 2008;9(3):231-239.
• 26. Leisy HB, Rastogi A, Guevara G, Ahmad M, Smith RT. The association of geographic atrophy and decreased renal function in patients with age-related macular degeneration. Eye (Lond). 2017;31(1):62-67.
• 27. Zipfel PF, Heinen S, Józsi M, Skerka C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol. 2006;43(1-2):97-106.